Caroline Dive | |
|---|---|
 Caroline Dive | |
| Born | April 1962 (age 62) |
| Alma mater | University of London (BPharm) |
| Scientific career | |
| Fields | Cancer Pharmacology |
| Institutions | Aston University University of Manchester Cancer Research UK |
| Thesis | Flow cytoenzymology with special reference to cancer chemotherapy (1988) |
| Website | www |
Caroline Dive CBE (born April 1962)[1] is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK (CRUK) Manchester Institute,[2][3] Director of the CRUK Manchester Institute Cancer Biomarker Centre[4] and co-director of the CRUK Lung Cancer Centre of Excellence.[5] She is the current President of The European Association for Cancer Research (EACR).[6]
Dive's citation upon election as Fellow of the Academy of Medical Sciences describes her as internationally renowned for her work on the development of liquid biopsy methods which use biomarkers circulating in the blood, such as circulating tumour cells and cell-free tumour DNA, to diagnose and monitor cancer.[7]
- ^ "Caroline DIVE". Companies House. Retrieved 4 April 2022.
- ^ "Caroline Dive Clinical and Experimental Pharmacology". cruk.manchester.ac.uk.
- ^ Holmes, David (2013). "Caroline Dive: leader in translational oncology research". The Lancet. 381 (9861): 107. doi:10.1016/S0140-6736(13)60036-7. ISSN 0140-6736. PMID 23312743. S2CID 19697388.
- ^ "CRUK MI Cancer Biomarker Centre". www.cruk.manchester.ac.uk. Archived from the original on 2019-12-09. Retrieved 2020-07-14.
- ^ "Lung Cancer Centre of Excellence", Cancer Research UK Lung Centre
- ^ "EACR Board | The European Association for Cancer Research". www.eacr.org. Retrieved 2020-07-14.
- ^ "Fellows directory", The Academy of Medical Sciences